Parameters of a severe disease course in ulcerative colitis

AIM: To detect high risk patients with a progressive disease course of ulcerative colitis (UC) requiring immunosuppressive therapy (IT). METHODS: A retrospective, multicenter analysis of 262 UC patients from eight German tertiary inflammatory bowel disease centres was performed. Patients were divided into two groups depending on the patients need to initiate immunosuppressive therapy in the disease course. A comparison between the two groups was made with regard to demographics, clinical and laboratory parameters obtained within three months after UC diagnosis and the response to first medical therapy. Using this data, a prognostic model was established to predict the individual patients probability of requiring an immunosuppressive therapy. RESULTS: In 104 (39.7%) out of 262 patients, UC therapy required an immunosuppressive treatment. Patients in this group were significantly younger at time of diagnosis (HR = 0.981 +/- 0.014 per year, P = 0.009), and required significantly more often a hospitalisation (HR = 2.5 +/- 1.0, P < 0.001) and a systemic corticosteroid therapy at disease onset (HR = 2.4 +/- 0.8, P < 0.001), respectively. Response to steroid treatment was significantly different between the two groups of patients (HR = 5.2 +/- 3.9 to 50.8 +/- 35.6 compared to no steroids, P = 0.016 to P < 0.001). Furthermore, in the IT group an extended disease (HR = 3.5 +/- 2.4 to 6.1 +/- 4.0 compared to proctitis, P = 0.007 to P = 0.001), anemia (HR = 2.2 +/- 0.8, P < 0.001), thrombocytosis (HR = 1.9 +/- 1.8, P = 0.009), elevated C- reactive protein (CRP) (HR = 2.1 +/- 0.9, P < 0.001), and extrain-testinal manifestations in the course of disease (HR = 2.6 +/- 1.1, P = 0.004) were observed. Six simple clinical items were used to establish a prognostic model to predict the individual risk requiring an IT. This probability ranges from less than 2% up to 100% after 5 years. Using this, the necessity of an immunosuppressive therapy can be predicted in 60% of patients. Our model can determine the need for an immunosuppressive drug therapy or if a "watch and wait" approach is reasonable already early in the treatment course of UC. CONCLUSION: Using six simple clinical parameters, we can estimate the patients individual risk of developing a progressive disease course. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.